Susquehanna Fundamental Investments’s Haemonetics HAE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-42,599	Closed	-$3.33M	–	1142
2024 Q4	$3.33M	Buy	+42,599	New	+$3.42M	0.05%	415
2023 Q3	–	Sell	-27,850	Closed	-$2.37M	–	472
2023 Q2	$2.37M	Sell	27,850 -35,032	-56%	-$2.96M	0.09%	227
2023 Q1	$5.2M	Sell	62,882 -11,091	-15%	-$898K	0.12%	215
2022 Q4	$5.82M	Hold	73,973	–	–	0.1%	259
2022 Q3	$5.48M	Buy	+73,973	New	+$5.31M	0.09%	302
2022 Q1	$4.41M	Sell	69,787 -4,560	-6%	-$248K	0.09%	328
2021 Q4	$3.94M	Buy	74,347 +28,910	+64%	+$1.76M	0.1%	258
2021 Q3	$3.21M	Buy	45,437 +36,308	+398%	+$2.29M	0.06%	436
2021 Q2	$608K	Sell	9,129 -5,598	-38%	-$396K	0.01%	1074
2021 Q1	$1.64M	Buy	+14,727	New	+$1.82M	0.03%	717

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Susquehanna Fundamental Investments's HAE Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Haemonetics (HAE) in Q1 2025, closing a stake of 42,599 shares — an estimated $3.33M sold.

Susquehanna Fundamental Investments first reported a position in HAE in Q1 2021 and held it in 10 quarters. The position peaked at $5.82M in Q4 2022. 314 funds tracked by Wall St. Rank hold HAE as of Q1 2025.

Susquehanna Fundamental Investments reported no remaining Haemonetics position as of Q1 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 42,599 Haemonetics shares in Q1 2025, an estimated $3.33M.
Susquehanna Fundamental Investments first reported a position in Haemonetics in Q1 2021 and held it in 10 quarters.
Susquehanna Fundamental Investments's Haemonetics position peaked at $5.82M in Q4 2022.
314 funds tracked by Wall St. Rank held Haemonetics as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.